Drug Trial Radar · NCT07655180
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
Jun 8, 2026
Primary completion
Aug 15, 2026
Study completion Aug 15, 2026
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receiving VYD2311, or a COVID-19 vaccine, or a combination of VYD2311 and a COVID-19 vaccine in healthy participants. This research study will measure the amount of serum virus neutralizing antibodies produced in the blood (antibodies that block a virus from infecting cells) and pharmacokinetics of VYD2311 compared to a COVID-19 vaccine, when each is administered alone or concurrently. Pharmacokinetics is the study of how a drug moves through the body, including how it is absorbed (taken into the body), distributed (spread throughout the body), metabolized (broken down in the body), and eliminated (removed from the body), and how the body affects the drug.
Conditions
- COVID-19
Interventions
COVID-19 mRNA vaccineDrug
A one-time dose of COVID-19 mRNA vaccine will be administered by intramuscular injection.
VYD2311Drug
A one-time dose of VYD2311 250mg will be administered by intramuscular injection.
Placebo (Normal Saline)Drug
A one-time dose of normal saline (placebo) administered by intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6Time frame: Through 6 days after dose
- Assessment of systemic reactions solicited via e-diary through day 6Time frame: Through 6 days after dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Invivyd Investigative Site
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.